Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS. 
  • Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
  • Collaborations : 
    - Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
    - Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
    - Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 3

ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
  • Project leader : Philippe Aftimos 
  • Collaborations : International clinical study
  • Funding (or) Support : Zenith Epigenetics Ltd.

Project 4

MULTICENTRIC PHASE II SINGLE-ARM STUDY OF NIVOLUMAB IN PATIENTS WITH TYPE B3 THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
  • Project leader : Thierry Berghmans
  • Collaborations : International clinical study
  • Funding (or) Support : EORTC

Project 5

AURA : Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Our team

Head of the Medical Oncology Clinic
Pr A. Awada

Solid Tumours / New Innovative drugs
Pr A. AwadaDr Ph. AftimosDr N. Kotecki

Solid and RareTumours
Pr A. AwadaDr Ch. Jungels

Breast Oncology
Pr M. PiccartDr D. de Valeriola
Dr Ph. AftimosDr A. Gombos
Pr Ch. SotiriouDr E. de Azambuja
Dr M. IgnatiadisDr F. Lebrun 
Dr L. BuisseretDr L. Polastro
Pr A. DrowartDr D. t’Kint de Roodenbeke
Dr M. Hanappe

Oncogeriatrics 
Dr L. Dal LagoDr L. Dumont (geriatrician)

Cervico-facial Oncology  
Dr Y. LalamiDr S. Luce

Skin Tumour Oncology                
Pr A. AwadaPr A. DrowartDr M. Langouo
Dr M. Suppa (dermatologue)

Digestive Oncology / Gastroenterology / Endoscopy
Dr A. HendliszDr F. Sclafani
Dr R. Saude Conde, Dr G. Bregni

Gynaecological Oncology
Dr L. PolastroDr F. Lebrun
Dr M. Langouo, Dr M. Hanappe

Thoracic Oncology
Pr Th. BerghmansDr M. Brandao
Dr Z. Mekinda

Urogenital, Bone and Soft Tissue Oncology
Dr Th. GilDr Ch. Jungels (sarcomas)
Dr N. Martínez-Chanza (urogenital tumors)

Dr S. Sideris (urogenital tumors)

Oncological Day Hospital
Dr D. de Valeriola
Dr Y. Lalami, Dr L. Polastro

Oncogenetics
Dr D. t’Kint de Roodenbeke

Neuro-oncology
Dr S. Luce

Psychooncology
Pr D. Razavi

Supportive and Palliative Cares / Pain Clinic
Dr I. LibertDr. V. Ligabo

Consultants :    
Pr J. Klastersky (internal medicine/oncology)
Dr A. Deleporte (digestive oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr J. Kerger (oncologie gynécologique/cutanée)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Dr L. Mans (digestive oncology)
Dr H. Rouvière (geriatry)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)
Dr Y. Wissam (medical oncology)

21/04/2022

 Scientific publications

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.

Authors : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE
Year : 2022
Journal : Cells
Volume : 11

Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.

Authors : Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT
Year : 2022
Journal : ESMO Open
Volume : 7
Pages : 100356

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Authors : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Year : 2022
Journal : Eur J Cancer

Frailty in older adults with cancer (Fabio Gomez, editor) - Part III : Breast cancer in older adults with frailty

Authors : Dal Lago L, De Caluwe A, Borghgraef C, Dumont L, Pepersack T
Year : 2022
Journal : Book
Volume : part III
Pages : 303 - 318

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Authors : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV
Year : 2022
Journal : Cancer Med
Volume : 11
Pages : 332-339